@MichaelAlbertMD The overlooked investing angle: the device makers treating exactly those conditions (CGMs, sleep apnea, ortho) got repriced as if GLP-1s would kill them. Device demand is actually rising, and the sector is its cheapest vs the market since 2008. https://t.co/jMaE6oRIa7
@gastroendonews Exactly the pattern the market keeps missing: GLP-1s combine with procedures and devices, they don't replace them. Same in CGMs (scripts rise on the drugs) and ortho (more reach surgical BMI). Yet device makers got repriced for substitution. https://t.co/jMaE6oRIa7
@VJNeurology This is the trial the market read as the end of CPAP makers. ResMed's own data went the other way: GLP-1 patients more likely to start CPAP, new users at record highs. The drug widens the diagnosed pool, but the fear repriced the sector anyway. https://t.co/jMaE6oRIa7
The most contrarian healthcare take I've read in a while. The market is convinced GLP-1 drugs are a wrecking ball for device makers. The operating data shows Ozempic feeding those markets, not starving them, and the sector is cheaper than it has been since 2008. Worth your time.
Still the most consequential conversation I've heard this year: @alapshah1 telling @kofinas the political system will come for the AI winners. Displacement taxes, an AI dividend fund, both parties drifting left on economics.
@BuffaloBillCo I think both are true, and that's the trick. Demand for the top of the distribution really is bottomless. Demand for the median credential is collapsing. The senior person who can verify work and take responsibility gets pricier, while the junior rungs they climbed are sawn off
@VijayGajeraO The gap is the story either way. 20M followers in six days costs nothing; 20,000 bodies in a field is expensive. Online reach now wildly overstates organisational power. But 40% graduate joblessness under 25 is the kind of number that eventually converts clicks into crowds.
@rationalaussie Agree, and it's a barbell. What survives is physical-world skill, plus work where someone has to put their name on the line: sign-offs, liability, trust. The squeeze zone is the middle, roughly 13% of US employment in generic cognitive work. That's the new commodity.
@TristinHopper Turchin's stat on this stuck with me: US lawyers roughly tripled between the 1970s and 2011, against population growth of about 45%. We mass-produced people for chairs that don't exist, and made the people who can fix and build things scarce. Canada just arrived early.
@Kalshi The underrated angle here: governments tax labour, AI pays capital. Every automated white-collar job is also a hole in the tax base. That's what turns a labour-market story into a political one.
@JaikyYadav16 Whoever ends up owning the protest, the number underneath doesn't move: about 40% of graduates under 25 in India are jobless (Azim Premji Univ). 20M Instagram followers in a week is the tell, not the crowd size. Educated, ambitious, no seats. That energy goes somewhere.